Aurobindo Pharma Limited — Updates, 09-11-2024: Press Release

Aurobindo Pharma Limited reported consolidated financial results for Q2 FY25, showing an 8% YoY increase in revenue from operations to INR 7,796 Cr. US formulations revenue rose 4.3% to INR 3,530 Cr, while Europe saw a 19% increase to INR 2,105 Cr. However, ARV revenue dropped 22.8% to INR 193 Cr. EBITDA before R&D grew by 16.1% YoY to INR 1,954 Cr. The net profit improved to INR 817 Cr, compared to INR 752 Cr in Q2 FY24.